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Introduction  
Esophageal achalasia is a primary motility disorder character-
ized by incomplete lower esophageal sphincter (LES) relaxation 
and loss of esophageal peristalsis.1 Consequently, the transit of 
swallowed food boluses through the esophagus is impaired and the 
patient typically experiences dysphagia. Backflow of saliva or undi-
gested food can cause heartburn, regurgitation or vomiting, chest 
pain, and respiratory symptoms such as nocturnal cough, recurrent 
breathing difficulty, and pneumonia. Achalasia is a chronic disease 
that causes progressive irreversible loss of esophageal motor func-
tion. Achalasia is difficult to diagnose early, but it is important to 
identify and treat the condition before irreversible changes occur.
Over the last decade, novel diagnostic modalities, such as 
high-resolution manometry (HRM), as well as treatment advanc-
es such as peroral endoscopic myotomy (POEM), have greatly 
improved the success rate of achalasia treatment. However, these 
developments remain unknown to most but few gastrointestinal 
(GI) motility experts. We need clinical guidelines for the diagnosis 
and management of achalasia based on evidence-based medicine 
that will help to inform healthcare providers and patients.
The guidelines describe approaches to the practical manage-
ment of adult patients with achalasia based on scientific evidence 
and expert consensus. The guidelines cover several options for the 
treatment of achalasia, summarize the benefits and harms of each, 
and provide information on the probable outcomes.
The present guidelines provide a practical, evidence-based 
guide for clinicians (gastroenterologists, upper GI tract sur-
geons, and general physicians), nurses, and paramedical teams. 
The guidelines are intended to help primary physicians and 
general health professionals to make achalasia management de-
cisions; the guidelines are also designed to provide educational 
resource for medical students and healthcare providers, and to 
provide patients with the most up-to-date information on their 
conditions.
Methods 
The guideline steering committee consisted of the Presidents 
and key members of the Korean Society of Neurogastroenterol-
ogy and Motility (KSNM) and Asian Neurogastroenterology and 
Motility Association (ANMA). This committee established the 
guideline development strategy and approved the project budget. 
Development of the guidelines began in June 2018. The working 
group comprises 38 expert gastroenterologists, surgeons and meth-
odologists, selected from among KSNM and ANMA members 
and other experts. Three workshops were conducted while develop-
ing the revised guidelines and the working group held 8 meetings.
The working group identified the most clinically significant 
questions using the nominal group technique.2 The guidelines 
were developed using both adaptation and de novo methods. The 
literature was searched for existing guidelines on achalasia. The 
search terms used were achalasia-related index words (“achalasia”) 
and guideline-related index words (“clinical protocols” OR “indi-
cation” OR “therapeutics” OR “therapy” OR “therapeutic use” 
OR “therapy*” OR “diagnosis” OR “guideline” OR “guidelines 
as topic” OR “guideline adherence” OR “practice guideline” OR 
Esophageal achalasia is a primary motility disorder characterized by insufficient lower esophageal sphincter relaxation and loss of 
esophageal peristalsis. Achalasia is a chronic disease that causes progressive irreversible loss of esophageal motor function. The recent 
development of high-resolution manometry has facilitated the diagnosis of achalasia, and determining the achalasia subtypes based 
on high-resolution manometry can be important when deciding on treatment methods. Peroral endoscopic myotomy is less invasive 
than surgery with comparable efficacy. The present guidelines (the “2019 Seoul Consensus on Esophageal Achalasia Guidelines”) 
were developed based on evidence-based medicine; the Asian Neurogastroenterology and Motility Association and Korean Society 
of Neurogastroenterology and Motility served as the operating and development committees, respectively. The development of 
the guidelines began in June 2018, and a draft consensus based on the Delphi process was achieved in April 2019. The guidelines 
consist of 18 recommendations: 2 pertaining to the definition and epidemiology of achalasia, 6 pertaining to diagnoses, and 10 
pertaining to treatments. The endoscopic treatment section is based on the latest evidence from meta-analyses. Clinicians (including 
gastroenterologists, upper gastrointestinal tract surgeons, general physicians, nurses, and other hospital workers) and patients could 
use these guidelines to make an informed decision on the management of achalasia.
(J Neurogastroenterol Motil 2020;26:180-203)
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“practice guideline as topic” OR “clinical guideline” OR “clinical 
practice guideline” OR “consensus” OR “recommendation” OR 
“workshop”). The inclusion criteria for the existing guidelines were 
as follows: (1) achalasia guidelines pertaining to adults, (2) written 
in English, and (3) published between January 2005 and July 2018. 
The exclusion criteria were as follows: (1) already developed via the 
adaptation process and (2) not supported by evidence-based medi-
cine. Eight guidelines were identified. A systematic review was also 
conducted, to identify clinical recommendations requiring an update 
due to new evidence, particularly pertaining to POEM and laparo-
scopic Heller myotomy (LHM). The Medline, EMBASE, and 
Cochrane Library databases were searched for all relevant studies 
published during the period 2000-2018. The following index terms 
were used as search queries: ([POEM] OR [endoscopic myoto-
my]) AND ([laparoscopic myotomy] OR [surgical myotomy] OR 
[Heller myotomy] or [Heller’s myotomy]). The inclusion criteria 
were as follows: (1) published in English, (2) published between 
2000 and 2018, and (3) pertaining to adult patients with achalasia. 
The exclusion criteria were as follows: (1) published in languages 
other than English, (2) animal studies, and (3) studies of adolescents 
or children (under the age of 19 years) (Supplementary Figure). We 
critically appraised the quality of the selected studies using the risk 
of bias tools described in the endoscopic treatment section developed 
by a de novo method and the Cochrane Risk of Bias Tool.3 The level 
of evidence for achalasia treatment recommendation was assessed 
based on the Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) system (Table 1).4 The treatment 
recommendations for primary esophageal achalasia were classified as 
“strong for” “weak for” “weak against” “strong against” or “no rec-
ommendation”. The evidence level, clinical applicability, and benefits 
and harms were the evaluation criteria.
Consensus was sought for the draft recommendations devel-
oped herein using the modified Delphi method.5 An expert panel 
comprising members of the KSNM and ANMA, and other 
experts, reviewed the draft. The first draft consisted of 18 recom-
mendations with one open question: 2 pertaining to the definition 
and epidemiology of achalasia, 6 pertaining to diagnoses, and 10 
pertaining to treatments. The first draft was sent via e-mail to the 
experts and their responses were anonymized. A score of more than 
4 on a 5-point Likert scale was considered to correspond to “agree” 
(with the recommendation in question); if more than two-thirds 
of all 47 respondents agreed with a recommendation, consensus 
was considered to have been reached thereon. Consensus was not 
reached on only 1 of the 18 recommendations on LHM. After the 
first round of appraisals, the working group presented the draft 
recommendations at an ANMA consensus meeting held on April 6, 
2019. A second round of appraisals, of the modified recommenda-
tion for LHM, achieved a 93.9% consensus (31/33 experts). Two 
Table 1. Levels of Evidence and Support for the Various Primary Esophageal Achalasia Treatment Recommendations4
Level of evidence
High At least one RCT or SR/meta-analysis with no concern regarding study quality 
Moderate At least one RCT or SR/meta-analysis with minor concerns regarding study quality or,
 at least one cohort/case-control/diagnostic test design study with no concern regarding study quality
Low At least one cohort/case-control/diagnostic test study with minor concerns regarding study quality,  
 or at least one single arm before-after study or, cross-sectional study with no concerns regarding study quality 
Very low At least one cohort/case-control/diagnostic test design study with serious concerns regarding study quality,  
 or at least one single arm before-after study or cross-sectional study with minor/severe concerns regarding study quality
Grade of recommendation
Strong for  The benefits of the intervention are greater than the harms based on a high or moderate level of evidence, 
 such that it can be strongly recommended for clinical practice in most cases.
Weak for  The benefits and harms of the intervention may vary depending on the clinical situation or patient characteristics.
 Recommended depending to the clinical situation.
Weak against  The benefits and harms of the intervention may vary depending on the clinical situation or patient characteristics.
 Intervention not be recommended for clinical practice.
Strong against  The harms of the intervention are greater than the benefits based on a high or moderate level of evidence,  
 such that it is not recommended for clinical practice.
No recommendation It is not possible to classify the recommendation owing to a lack of evidence or equivocal results.  
 Further evidence is needed.
RCT, randomized controlled trial; SR, systematic review.
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external experts (Y.T.B. [South Korea] and S.G [Thailand] re-
viewed the recommendations in terms of necessity, appropriateness, 
health care setting, level of care, and balance between benefits and 
harms. The final 18 recommendations/guidelines, and a flowchart 
for the diagnosis and treatment of esophageal achalasia, are pre-
sented in Table 2 and Figure 1, respectively.
This project was funded by the KSNM; there was no external 
source of support. All members of the working team confirmed via 
e-mail that they had no conflicts of interest related to the develop-
ment of the guidelines, which will be updated every 3 to 5 years to 
take account of new evidences accumulated.
Definition and Epidemiology of Achalasia  
Definition
Statement 1: Achalasia is a primary motor disorder 
of the esophagus characterized by insufficient lower 
esophageal sphincter relaxation and loss of esophageal 
peristalsis.
 (Level of evidence, not applicable; strength of recommenda-
tion, not applicable)
 Experts’ opinions: agree strongly (78.2%), agree with some 
reservations (19.6%), undecided (0.0%), disagree (2.2%), and 
disagree strongly (0.0%)
Achalasia is a primary esophageal motor disorder characterized 
by incomplete LES relaxation and an absence of esophageal peri-
stalsis.1 The cause of achalasia is not clear yet. Idiopathic achalasia 
occurs secondary to destruction of the myenteric plexus, which in-
volves both peristaltic contraction and LES relaxation.6 The clinical 
presentation includes dysphagia to solids and liquids, regurgitation 
of bland undigested food or saliva, chest pain during eating, and 
weight loss. Objective symptom scoring systems, such as the Eck-
ardt score, are important for determining the treatment response 
(Table 3).1 A subset of patients with achalasia experience heartburn, 
which often leads to misdiagnosis of achalasia as gastroesophageal 
reflux disease (GERD).7 Achalasia can be diagnosed based on ma-
nometry, esophagography, or endoscopy findings.1 Pseudoachalasia, 
which shows similar clinical features but is caused by cancer or Try-
panosoma cruzi infection, should be excluded.8
Epidemiology of Achalasia
Statement 2: Achalasia is a very rare disorder of the 
esophagus that affects both sexes equally and is fre-
quently diagnosed in patients aged 40 to 60 years.
 (Level of evidence, not applicable; strength of recommenda-
tion, not applicable)
 Experts’ opinions: agree strongly (34.8%), agree with some 
reservations (54.4%), undecided (6.5%), disagree (4.3%), and 
disagree strongly (0.0%)
Malignancy, peptic stricture with
acid reflux, structural disorder
such as esophageal webs and





*For helpful for diagnosis and estimation of the severity and treatment
response of achalasia by time barium esophagograpjy (TBE)
**Gold standard for diagnosis and classification of subtypes of
achalasia
Botulinum toxin injection/+ oral
pharmaceutical agents






Figure 1. Flowchart of the management 
of esophageal achalasia.
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Achalasia is a rare esophageal motility disorder. Population-
based epidemiological data on achalasia are sparse and most existing 
studies used a retrospective design.9 According to studies conducted 
in the 2000s, the incidence of achalasia is increasing and does not 
differ according to ethnicity. The incidence of achalasia is 0.03-0.27 
per 100 000 persons per year in developing countries (Fig. 2).10,11 A 
recent large cohort study based on Dutch healthcare insurance data 
revealed an incidence of achalasia of 2.2 per 100 000 persons per 
Table 2. Summary of Recommendations/Guidelines for Primary Esophageal Achalasia
Statement
Level of  
evidence
Strength of  
recommendation
Definition and epidemiology of achalasia
1. Achalasia is a primary motor disorder of the esophagus characterized by insufficient lower esophageal
 sphincter relaxation and loss of esophageal peristalsis.
NA NA
2. Achalasia is a very rare disorder of the esophagus that affects both sexes equally and is frequently 
 diagnosed in patients aged between 40 and 60 years.
NA NA
Diagnosis of esophageal achalasia
    Esophageal manometry
3. Esophageal manometry is a gold standard test for diagnosis of achalasia. Low Strong
4. High-resolution manometry is superior to conventional manometry for the diagnosis of achalasia. Low Strong
5. The Chicago classification is a useful tool to define the clinically relevant phenotypes of achalasia. Moderate Strong
    Barium esophagography
6. Barium esophagography is recommended to diagnose achalasia in patients with esophageal dysphagia. Low Strong
7. Timed barium esophagography is useful for assessing the severity of achalasia, and for evaluating
 treatment outcomes.
Moderate Strong
    Endoscopy
8. Endoscopic assessment is recommended for achalasia patients to rule out pseudoachalasia caused 
 by cancer or other esophageal diseases (eg, peptic stricture with acid reflux, structural disorders such
 as esophageal webs and rings, or esophageal inflammation).
Low Strong
Treatment of esophageal achalasia
    Oral pharmacologic treatment
9. Oral pharmacologic therapy can be considered for achalasia whose general condition renders them
 unsuitable for endoscopic treatment or surgery.
Low Weak
    Botulinum toxin injection
10. Botulinum toxin injection is recommended for achalasia patients whose general condition renders them 
 unsuitable for endoscopic treatment or surgery.
Moderate Strong
    Pneumatic balloon dilatation
11. Pneumatic balloon dilatation is recommended as an initial treatment for patients with achalasia. Moderate Strong
    Peroral endoscopic myotomy
12. The outcomes of peroral endoscopic myotomy are comparable to those of Heller myotomy for 
 treatment-naïve patients with achalasia.
Moderate Strong
13. Peroral endoscopic myotomy, rather than Heller myotomy, should be considered for the treatment of 
 type III achalasia because enables extended myotomy.
Low Weak
14. Acid suppressive therapy is recommended for patients with reflux symptoms or esophageal erosion
 undergoing peroral endoscopic myotomy, to prevent esophageal stricture.
Low Strong
    Surgical treatment
15. Laparoscopic Heller myotomy can be considered as one of first-line therapies for achalasia patients,
 and has similar expected clinical outcomes to pneumatic balloon dilation.
Moderate Weak
16. Partial fundoplication in addition to LHM is recommended to reduce the risk of subsequent GERD. Low Strong
    Management of recurrence of achalasia after initial treatment
17. Peroral endoscopic myotomy is recommended for achalasia patients who failed initial endoscopic treatment. Moderate Strong
18. Peroral endoscopic myotomy can be considered as a rescue treatment for achalasia patients.
 who were not treated successfully by laparoscopic Heller’s myotomy.
Low Weak
NA, not applicable; LHM, laparoscopic Heller myotomy; GERD, gastroesophageal reflux disease.
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year,9 compared to 2.9 per 100 000 persons in a study using tertiary 
hospital data.12 The prevalence of achalasia also appears to be in-
creasing slightly. A Dutch study reported a prevalence rate of 15.3 
per 100 000 persons,9 and other studies have reported prevalence 
rates of 2.5-32.6 per 100 000 persons.12,13 However, Kim et al14 
reported that the incidence and prevalence of achalasia were 0.4 and 
6.3 per 100 000 persons, respectively, in population-based studies 
based on a Korean national healthcare database.
The numbers of male and female patients with achalasia 
were similar in several large-scale epidemiological studies.9,11,14,15 
Although achalasia can occur at any age, it is most prevalent in pa-
tients aged 40 to 60 years.9,11,16 Asian epidemiological studies have 
reported similar data to Western studies.
Diagnosis of Achalasia  
Esophageal Manometry
Esophageal manometry is essential for assessing esophageal 
motor function in patients with achalasia.1 Barium esophagography 
and esophagogastroduodenoscopy (EGD) are used as comple-
mentary tests to manometry in the diagnosis and management of 
achalasia.17,18 However, neither EGD nor barium esophagography 
alone is sensitive enough to achieve a definitive diagnosis. EGD 
can be used as a supportive tool for diagnosis of achalasia in only 
one-third of patients, and esophagography in up to two-thirds of 
patients. Thus, patients suspected to have achalasia but who have 
shown normal results in EGD or esophagography studies must 
undergo esophageal motility tests. However, in patients with EGD 
or esophagography findings typical of achalasia, esophageal motility 
tests should be performed to confirm the diagnosis.
Statement 3: Esophageal manometry is a gold standard 
test for the diagnosis of achalasia.
(Level of evidence, low; strength of recommendation, strong)
 Experts’ opinions: agree strongly (76.1%), agree with some 
reservations (23.9%), undecided (0.0%), disagree (0.0%), and 
disagree strongly (0.0%)
Manometric findings of aperistalsis and incomplete LES re-
laxation without evidence of mechanical obstruction supports the 
diagnosis of achalasia (Fig. 3A). Other findings, such as increased 
Table 3. Eckardt Score for Clinical Classification of Achalasia Severity
Score Dysphagia Regurgitation Retrosternal pain Weight loss (kg)
0 None None None None
1 Occasional Occasional Occasional < 5
2 Daily Daily Daily 5-10






















Figure 2. Reported incidence and 
prevalence rates of achalasia. Data are 
expressed as rates per 100 000 persons 
per year (incidence/prevalence).
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basal LES and baseline esophageal body pressure with simultaneous 
non-propagating contractions, are also suggestive of achalasia, but 
are not required for its diagnosis. Though rare, variants of achalasia 
differing in the degree of incomplete LES relaxation and aperistalsis, 
as well as some characterized by complete LES relaxation, have been 
described.19 Aperistalsis has been defined as a lack of esophageal 
body peristalsis and can present with different pressure patterns, such 
as a “quiescent” esophageal body, isobaric panesophageal pressuriza-
tion, and simultaneous contractions. Achalasia variants presenting 
with propagating contractions, which could represent either early 
achalasia or, most commonly, a subclinical mechanical obstruction at 
the esophago-gastric junction, have also been described. This het-
erogeneity demonstrates the need for motility studies, where motor 
patterns can affect diagnosis and management.
Statement 4: High-resolution manometry is superior to 
conventional manometry for the diagnosis of achalasia.
(Level of evidence, low; strength of recommendation, strong)
 Experts’ opinions: agree strongly (71.8%), agree with some 
reservations (23.9%), undecided (4.3%), disagree (0.0%), and 
disagree strongly (0.0%)
Data are emerging suggesting that HRM may have greater 
sensitivity for diagnosing achalasia than conventional manom-
etry.20 Conventional manometric techniques and tracing analysis 
(interval of 3-5 cm) can be utilized to depict the pressure profile 
of the smooth muscle esophagus; however, with HRM, the whole 
esophagus can be analyzed, which is useful for predicting not only 
the presence of achalasia, but also the treatment response. Esopha-
geal pressure topography enables the differentiation of achalasia 
into 3 subtypes, which has implications for treatment outcomes.20 
Although these achalasia subtypes can be defined by careful analysis 
of conventional tracings, they can be distinguished more easily and 
reproducibly by HRM.21
Statement 5: The Chicago classification is useful for 
defining the clinically relevant phenotypes of achalasia.
 (Level of evidence, moderate; strength of recommendation, 
strong)
 Experts’ opinions: agree strongly (50.0%), agree with some 
reservations (45.7%), undecided (4.3%), disagree (0.0%), and 
disagree strongly (0.0%)
Based on the relaxation pressure and propagation and pressur-
ization parameters, the Chicago classification 3.0 is a system for clas-
sifying achalasia into distinct subtypes (I-III) and variants, ie, early 
achalasia with esophagogastric junction (EGJ) outflow obstruction 
(EGJOO) and achalasia associated with hypotonic LES (absence 
of contractility) (Fig. 3B).19-21 Type I achalasia, called classic acha-
lasia, is characterized by an absence of esophageal body smooth 
muscle contractility and no esophageal pressurization. These find-
ings are more typical of late-stage achalasia, in which there is loss of 
muscle tone and subsequent dilation of the esophageal body. Type 
II achalasia, which is the most common type, is characterized by pe-
riods of esophageal pressure and compression; the smooth muscle 
of the esophagus retains its tone and there is absent peristalsis with 
abnormal pan-esophageal high-pressure patterns. If 20.0% or more 
of the patient’s swallows are characterized by this panesophageal 
pressurization, the achalasia is classified as type II. Type III acha-







B Achalasia type I Achalasia type II Achalasia type III
Figure 3. Manometric findings of esophageal achalasia. A. Conventional esophageal manometry findings of achalasia. Achalasia is characterized by 
incomplete lower esophageal sphincter (LES) relaxation upon deglutition, defined as a residual pressure > 10 mmHg, and aperistalsis in the body 
of the esophagus. In addition, the resting tone of the LES will often be elevated. B. Subtypes of esophageal achalasia identified by high-resolution 
manometry: type I, classic achalasia with no evidence of pressurization; type II, panesophageal pressurization; and type III, vigorous achalasia or 
spastic contractions of the distal esophageal segment.
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contraction of the distal esophagus in at least 20.0% of swallows.
The achalasia subtypes have been linked to the treatment re-
sponse in multiple studies, including a recent systematic review and 
meta-analysis of manometric findings.22 These findings should be 
used to guide treatment decisions. Multiple studies have reported 
different treatment success rates among the 3 achalasia subtypes, 
particularly, type III showing a higher likelihood of treatment failure 
compared to type II achalasia.22,23 The inferior response of type III 
patients is often attributed to spastic contractions in the esophageal 
body. Pratap and colleagues found that type II predicted a good 
response to pneumatic dilatation.24 The European Achalasia Trial 
showed that treatment success rates for type II achalasia were high 
for both LHM (93.0%) and pneumatic balloon dilation (PBD; 
100.0%).25 The follow-up data of the same trial confirmed that type 
III achalasia is indeed an important predictor of treatment failure, at 
least for PBD. Studies of LHM also found type III achalasia to be 
predictive of a poor treatment outcome. Patients with type III acha-
lasia had the highest incidence of failure (22.2% vs 3.0% and 3.4% 
for types I and type II, respectively; P = 0.01).26-28 Finally, four 
studies reported that type III achalasia was associated with failure of 
POEM treatment.23,29-31
Barium Esophagography
Statement 6: Barium esophagography is recom-
mended to diagnose achalasia in patients with esopha-
geal dysphagia.
(Level of evidence, low; strength of recommendation, strong)
 Experts’ opinions: agree strongly (39.1%), agree with some 
reservations (54.4%), undecided (6.5%), disagree (0.0%), and 
disagree strongly (0.0%)
Barium esophagography is recommended to assess esophageal 
emptying and EGJ morphology in those with equivocal motility test 
results.32 The diagnosis of achalasia can be supported by esopha-
gographic findings, including dilation of the esophagus, a narrow 
EGJ with a “bird-beak” appearance, aperistalsis, and poor empty-
ing of the barium (Fig. 4A).33 In advanced cases, a dilated esopha-
geal body and high air-fluid level, in the absence of an intragastric 
air bubble or even a sigmoid-like appearance of the esophagus, may 
be present.
Statement 7: Timed barium esophagography enables 
assessment of the severity of achalasia and evaluation of 
the treatment outcome.
 (Level of evidence, moderate; strength of recommendation, 
strong)
 Experts’ opinions: agree strongly (34.8%), agree with some 
reservations (58.7%), undecided (6.5%), disagree (0.0%), and 
disagree strongly (0.0%)
Timed barium esophagography (TBE) is a reproducible tech-
nique for estimating esophageal emptying with very high inter-










1 min 2 min 5 min
A B
Figure 4. Esophagographic findings of esophageal achalasia. A. Barium swallow typically reveals a “bird-beak” appearance of the esophagogastric 
junction, with a dilated esophageal body and an air-fluid level in the absence of an intragastric air bubble, or even a sigmoid-like appearance (in 
advanced cases). B. Timed barium esophagography for measuring esophageal emptying at 1, 2, and 5 minutes. The barium column height is mea-
sured from the end of the esophagus.
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the patient in the upright position. The patient is instructed to drink 
100-250 mL of low-density barium and the barium column height is 
measured from the end of the esophagus; the height at 5 minutes is 
used to determine the completeness of emptying.34 TBE predicts the 
likelihood of symptom recurrence after PD or surgical myotomy.35 
Rohof et al34 found that esophageal retention was a good predictor 
of treatment failure in cases of long-standing achalasia and proposed 
basing the decision for retreatment on the TBE rather than manom-
etry. Moreover, studies using TBE showed that it improved diagno-
sis and prediction of treatment outcome. In a recent study including 
achalasia patients, and those with EGJOO or dysphagia of other 
origin, a barium column height of 5 cm after 1 minute showed the 
highest sensitivity and specificity (of 94.0% and 71.0%, respectively) 
for differentiating untreated achalasia from EGJOO and non-
achalasia based on receiver operating characteristic analysis.36
Endoscopy
Statement 8: Endoscopic assessment is recommended 
for achalasia patients to rule out pseudoachalasia 
caused by cancer and other esophageal diseases (eg, 
peptic stricture with acid reflux, structural disorders 
such as esophageal webs and rings, or esophageal in-
flammation).
(Level of evidence, low; strength of recommendation, strong)
 Experts’ opinions: agree strongly (78.2%), agree with some 
reservations (19.6%), undecided (2.2%), disagree (0.0%), and 
disagree strongly (0.0%)
EGD has a low diagnostic yield for achalasia; its primary role 
is exclusion of mechanical obstruction secondary to a peptic stric-
ture or cancer in patients with dysphagia.16 EGD can also rule out 
reflux esophagitis, structural lesions (strictures, webs, or rings), and 
eosinophilic esophagitis. A tumor infiltrating the gastroesophageal 
junction and cardia can mimic the clinical, radiological, and mano-
metric findings of achalasia, resulting in impaired LES relaxation, 
esophageal dilatation, and absence of peristalsis. This condition is 
defined as “secondary achalasia” or “pseudoachalasia.” Similar to 
the manometric features of achalasia, mechanical obstruction can 
result in both impaired EGJ relaxation and abnormal esophageal 
body function (aperistalsis or spastic contractions).
Dysphagia to solids and liquids, short-duration dysphagia (< 1 
year), serious weight loss (> 6.8 kg), and age over 55 years should 
lead to suspicion of secondary achalasia; however, these signs are 
neither sensitive nor specific.37 Thus, in patients with HRM or 
esophagography findings of achalasia, endoscopic evaluation of the 
EGJ and cardia is needed to ensure that there is no infiltration of 
cancer. Mucosal ulceration or nodularity, reduced compliance of the 
EGJ, or an inability to pass the endoscope into the stomach are the 
most common endoscopic findings of pseudoachalasia. Endoscopic 
mucosal biopsy is used to diagnose secondary pseudoachalasia. 
When biopsy is negative but secondary achalasia is suspected, com-
puted tomography or endoscopic ultrasonography can help to rule 
out pseudoachalasia.38,39
In idiopathic achalasia, the endoscopic findings at the EGJ 
range from normal-appearing (in about 40% of patients) to a thick-
ened muscular ring that may have a rosette configuration on retro-
flexion, accompanied by signs of esophagitis such as friability, thick-
ening, and even erosion secondary to food stasis (Fig. 5), as well 
as mild-to-moderate resistance to intubation of the EGJ.40 Saliva, 
liquid, and undigested food material may be seen in the esophagus 
in the absence of mucosal abnormality or tumor.1 As the disease 
progresses, luminal dilation and tortuosity make the diagnosis more 
obvious.41,42 Although endoscopy may suggest achalasia, other tests 
must be performed to confirm the diagnosis.
Figure 5. Endoscopic findings of esopha-
geal achalasia. A dilated esophagus show-
ing food stasis, saliva and some resistance 
at the gastroesophageal junction.
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Treatment of Esophageal Achalasia  
The goal of achalasia treatment is to promote relief of dyspha-
gia and related complications. Several treatments can be tailored 
according to the patient’s overall health status. However, there is no 
specific therapy targeting the underlying disease process, because 
the pathogenesis of the impaired esophageal peristalsis and poor 
esophageal sphincter relaxation are unclear.
PBD, POEM, and LHM provide similarly effective long-
term results for esophageal achalasia. In patients whose condition is 
too poor for endoscopic treatment or surgery, botulinum injection 
or oral medication might be helpful.
Oral Pharmacologic Treatment
Statement 9: Oral pharmacologic therapy can be con-
sidered for achalasia patients whose medical condition 
is unsuitable for endoscopic treatment or surgery.
(Level of evidence, low; strength of recommendation, weak)
 Experts’ opinions: agree strongly (21.8%), agree with some 
reservations (50%), undecided (21.8%), disagree (6.5%), and 
disagree strongly (0.0%)
Uncontrolled and small studies reported that a number of 
pharmacological agents, including calcium channel blockers, ni-
trates, anticholinergics, phosphodiesterase inhibitors, and ß-adren-
ergic agonists, have been used for treating achalasia. These agents 
are effective in reducing LES pressure and temporarily relieving 
dysphagia, but do not improve LES relaxation or peristalsis.43 
Calcium channel blockers transiently decrease LES pressure by 
13.0-49.0%, facilitate esophageal emptying and improve symptom 
severity by 0.0-77.0%.44-47 Calcium channel blockers are associated 
with side effects, such as headache, hypotension, and peripheral 
edema.48 Anticholinergics (eg, cimetropium bromide) decrease 
LES pressure and accelerate esophageal transit. A double-blind, 
placebo-controlled trial showed that cimetropium bromide reduced 
LES pressure by 70.0% for about 45 minutes, and improved 
esophageal transit.49 The clinical response to pharmacologic agents 
is short-lived; they do not provide complete relief of symptoms and 
efficacy decreases substantially over time.45 Thus, these agents are 
commonly reserved for patients who cannot, or refuse to, undergo 
endoscopic or surgical therapy, and for those who have failed endo-
scopic or surgical therapy.
Botulinum Toxin Injection
Statement 10: Botulinum toxin injection is recom-
mended for achalasia patients whose medical condition 
is unsuitable for endoscopic treatment or surgery.
 (Level of evidence, moderate; strength of recommendation, 
strong)
 Experts’ opinions: agree strongly (42.5%), agree with some 
reservations (42.5%), undecided (10.7%), disagree (4.3%), and 
disagree strongly (0.0%)
Injection of botulinum toxin into the LES has been shown 
to improve the symptoms of achalasia (dysphasia, regurgitation, 
and chest pain), decrease the LES pressure, improve esophageal 
emptying, and increase the size of the LES aperture compared to 
injection of placebo (Table 4).50,51 However, although multiple trials 
have demonstrated short-term benefits of botulinum toxin injection, 
a single injection of botulinum toxin has only short-duration clinical 
effects with relapses within several months occurring frequently.51-59
Typically, 100 U of botulinum toxin is injected into 4 quadrant 
of LES each as 4 divided doses. There is wide variability in the 
timing of the botulinum toxin injections. A multicenter randomized 
study found no clear dose-response effect (doses of 50, 100, or 200 
U) after 1 month, but 2 injections of 100 U botulinum toxin, 30 
days apart, was the most effective therapeutic schedule.60 According 
to a 9-year retrospective chart review, botulinum toxin was used in 
21.0% of achalasia patients. Symptom improvement persisted for a 
mean of 6.2 months, with a need for repeated injections (mean, 1.7; 
range: 1-7), and about 43.0% of patients required different, addi-
tional treatments.61
Botulinum toxin injection can induce esophageal perforation 
or, inflammatory mediastinitis62 and chest pain (4.3%) or heartburn 
(0.7%),58 but it is a relatively safe treatment because of the low 
probability of complications. Botulinum toxin injection is less effica-
cious than PBD and myotomy in inducing long-term remission of 
achalasia.51,63 However, if myotomy or PBD cannot be performed 
because the patient is in poor general condition, repeated botulinum 
toxin injection should be considered. Following repeated botulinum 
toxin injection, 50.0% of patients were asymptomatic. The median 
duration of the symptom-free period was 11.5 months after the first 
botulinum injection, and 10.5 months after the second.63
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Pneumatic balloon dilatation
Statement 11: Pneumatic balloon dilatation is recom-
mended as an initial treatment for patients with achalasia.
 (Level of evidence, moderate; strength of recommendation, 
strong)
 Experts’ opinions: agree strongly (26.1%), agree with some 
reservations (54.4%), undecided (13.0%), disagree (6.5%), and 
disagree strongly (0.0%)
One of the most frequently used treatments for achalasia is 
PBD of the LES.59,64-72 Treatment parameters such as balloon size, 
number of dilations, inflation pressure, and duration vary according 
to the specialists or institutions. Depending on the general condi-
tion of the patient, graded PBD (with 30-mm, 35-mm, or 40-mm 
balloons) is considered one of the primary options for achalasia.73 
According to a retrospective analysis of 209 patients, management 
of achalasia with initial dilation can provide good or excellent long-
term results and high patient satisfaction rates.74 A prospective 
randomized European study of PBD and LHM reported that the 
therapeutic success rate was not significantly different between the 
1- and 2-year follow-ups (P = 0.46). Also, there was no significant 
difference in the pressure at the LES (P = 0.27) or esophageal 
emptying, as assessed by the height of the barium column (P = 
0.21) (Table 5).59,64-72
Peroral endoscopic myotomy
Statement 12: The outcomes of peroral endoscopic 
myotomy are comparable to those of laparoscopic 
Heller myotomy for treatment-naïve patients with 
achalasia.
 (Level of evidence, moderate; strength of recommendation, 
strong)
 Experts’ opinions: agree strongly (63.0%), agree with some 
reservations (37.0%), undecided (0.0%), disagree (0.0%), and 
disagree strongly (0.0%)
LHM is a first-line treatment for achalasia that achieved 
excellent outcomes in 91.8% of patients after a follow-up of 83.2 
months.75,76 However, LHM is an invasive and expensive proce-
dure that requires general anesthesia.77,78 Previous meta-analyses of 
POEM showed a clinical success rate of 98.0%.79,80 In meta-analy-
sis of the present guidelines, the clinical efficacy rate of POEM was 
92.8% (95% confidence interval [CI], 91.1-94.1%) for the naïve 
and prior treatment-failed patients combined, and 93.7% (95% 
CI, 86.7-97.1%) for naïve patients. Additionally, in another meta-
analysis, the postoperative Eckardt score was better for patients who 
underwent POEM versus those who underwent LHM (Fig. 6).81-
86 Recent guidelines for achalasia stated that POEM has an efficacy 
similar to that of LHM.87 A study with a 3-year follow-up showed 
that POEM was comparable to LHM in terms of the postopera-
tive Eckardt score and quality of life.88 A large, recently published 
large cohort study, with long-term follow-up, showed that the 
clinical success rate of POEM was 87.0% after a median follow-
up of 49 months.89 Reflux-related adverse events can occur with 
both POEM and LHM. However, in contrast to LHM, which 
requires partial fundoplication to reduce pathologic acid reflux, 
POEM is typically performed without any anti-reflux procedure.90 
Previous meta-analyses reported that acid reflux occurs more fre-
quently after POEM than after LHM.91,92 However, there was 
no difference in the rate of reflux symptoms, pathologic acid reflux, 
or the requirement for proton pump inhibitors (PPIs) between the 
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1.1.1 Post-operative eckardt score
POEM heller myotomy
Figure 6. Meta-analysis comparing peroral endoscopic myotomy (POEM) and laparoscopic Heller myotomy (LHM). During the 3-year follow-
up, POEM is comparable to LHM in terms of the postoperative Eckardt score. 
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In summary, the high clinical efficacy of POEM, and the ac-
ceptable adverse event rate, are similar to those of LHM for treat-
ment-naïve patients with achalasia. Nevertheless, long-term follow-
up studies are required to define the role of POEM in the initial 
endoscopic treatment of achalasia.
Statement 13: Peroral endoscopic myotomy, rather 
than laparoscopic Heller myotomy, can be considered 
for the treatment of type III achalasia because it can of-
fer extended myotomy.
(Level of evidence, low; strength of recommendation, weak)
 Experts’ opinions: agree strongly (43.4%), agree with some 
reservations (37.0%), undecided (17.4%), disagree (2.2%), and 
disagree strongly (0.0%)
Previous studies reported different success rates among the 3 
achalasia subtypes; in particular, type III achalasia was associated 
with an increased risk of treatment failure compared to type II acha-
lasia.22,23 Type III achalasia is characterized by pathological mecha-
nisms involving the esophageal body and the LES.93 Therefore, the 
response rate to PBD or botulinum toxin injection is relatively low 
in patients with type III achalasia. In a study that reported treatment 
response according to achalasia subtype, the clinical success rate of 
the first session of PBD was 38.0% (3/8) for type I achalasia, 73.0% 
(19/26) for type II achalasia, and 0.0% (0/11) for type III achalasia.34 
Botulinum toxin injection also showed low efficacy in patients with 
type III achalasia (type I, 0.0% [0/2]; type II, 86.0% [6/7]; type 
III, 22.0% [2/9]). In another study, the treatment response of PBD 
was 63.0% in type I achalasia, 90.0% in type II achalasia, and 33.0% 
in type III achalasia.24 Myotomy may have greater efficacy for the 
treatment of type III achalasia compared to PBD. A study involving 
18 patients with type III achalasia demonstrated that LHM tended 
to have a clinical success rate superior to that of PBD, although the 
difference was not significant (86.0% vs 40.0%, P = 0.12).94
Although the treatment response rate of type III achalasia pa-
tients undergoing LHM is higher than that of those undergoing 
PBD, the efficacy of LHM for type III achalasia is inferior to that 
for other types of achalasia. In a previous study on LHM in pa-
tients with achalasia, the clinical success rate was 85.0%, 95.0%, and 
70.0% for type I, type II, and type III achalasia, respectively (P < 
0.001).31
Unlike conventional treatments, such as PBD and LHM, 
POEM enables extended myotomy in patients with type III acha-
lasia. Meta-analysis of studies comparing POEM and LHM 
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POEM than LHM. Also, operation time and length of hospital 
stay tended to be shorter for POEM than LHM. Another meta-
analysis, of 8 studies on POEM for type III achalasia, demonstrat-
ed an overall clinical success rate of 91.6% (Table 6).92,95 Moreover, 
a multi-center retrospective cohort study including 75 patients with 
type III achalasia showed that the clinical response rate was higher 
in patients who underwent POEM than in those who underwent 
LHM (98.0% vs 81.0%, P = 0.01).92
The overall rate of adverse events in type III achalasia patients 
who underwent POEM was 11.2% in the meta-analysis discussed 
above.96 More than 70.0% of adverse events could be managed 
conservatively without further intervention. In some patients, the 
length of hospital stay was prolonged due to adverse events includ-
ing pulmonary embolism, pneumothorax, capnoperitoneum, and 
bleeding. Inadvertent mucosotomies occurred in 3.0% of patients, 
who were managed by clipping.96 The rate of adverse events in 
patients with type III achalasia undergoing POEM seems to be ac-
ceptable.
Although large-scale randomized controlled trials (RCTs) 
are lacking, current evidence supports superior clinical efficacy of 
POEM over LHM in patients with type III achalasia, where the 
length of myotomy is greater for the former treatment modality. 
Given that, for patients with type III achalasia, the clinical success 
rate of POEM is good and the adverse event rate is acceptable, 
we recommend POEM over LHM for the treatment of type III 
achalasia.
Statement 14: Acid suppressive therapy is recommend-
ed for patients with reflux symptoms or esophageal 
erosion after peroral endoscopic myotomy, to prevent 
esophageal stricture.
(Level of evidence, low; strength of recommendation, strong)
 Experts’ opinions: agree strongly (47.8%), agree with some 
reservations (50.0%), undecided (2.2%), disagree (0.0%), and 
disagree strongly (0.0%)
One of the main adverse events associated with POEM is 
gastroesophageal reflux. Unlike LHM, in POEM no anti-reflux 
procedure is performed; however, no alteration of the diaphragmatic 
and gastroesophageal anatomy occurs in POEM, which potentially 
reduces the risk of reflux. Gastroesophageal reflux is evaluated after 
POEM according to symptoms, pH, and endoscopic findings. In 
meta-analysis of the present guidelines, the overall rates of reflux 
symptoms, abnormal pH, and reflux esophagitis, according to en-
doscopic examinations, were 20.3% (95% CI, 16.9-24.3%), 24.7% 
(95% CI, 20.0-30.0%), and 42.6% (95% CI, 34.1-51.5%), respec-
tively. However, there is no significant difference of development of 
GERD between POEM and LHM (Fig. 7).
Although the definitions of symptoms, abnormal pH, and 
abnormal endoscopic findings were not standardized across the 
studies, POEM is clearly associated with an increased risk of post-
procedural reflux. Therefore, acid suppressive therapy is recom-
mended after POEM for patients with reflux symptom or esopha-
gitis. Also, there is a dissociation among the rate of abnormal acid 
exposure and the rates of reflux symptoms and reflux esophagitis 
based on endoscopic examinations. Therefore, clinicians should 
evaluate asymptomatic patients via regular endoscopy examinations 
or pH monitoring.
In a previous meta-analysis, the rate of PPI use after POEM 
ranged from 2.6% to 27.8% (pooled estimate, 10.6%; 95% CI, 6.5-
17.3%).90 However, the optimal duration and dose of PPI use are 
controversial. Most patients with post-procedural gastroesophageal 
reflux can be treated using a standard PPI dose. Also, the long-
term effects of an abnormal pH in asymptomatic participants are 
unclear. Therefore, a short course of PPIs is recommended after 
POEM, although a more tailored approach based on symptoms, 
pH and endoscopy findings appears to be more appropriate.
Surgical Treatment
Statement 15: Laparoscopic Heller myotomy can be 
considered a first-line therapy for achalasia patients, 
and has similar expected clinical outcomes to pneu-
matic balloon dilation.
 (Level of evidence, moderate; strength of recommendation, 
weak)
 Experts’ opinions: agree strongly (18.2%), agree with some 
reservations (75.8%), undecided (3.0%), disagree (3.0%), and 
disagree strongly (0.0%)
Surgical myotomy, also known as Heller myotomy, disrupts 
the muscle fibers of the LES. LHM is the preferred surgical 
technique because of its low morbidity rate and the rapid rate of re-
covery.97,98 In a systematic review involving 3086 patients, symptom 
improvement after LHM was achieved in 89.3% after a mean of 
35.4 months (range: 8-83 months).97 Two prospective, randomized 
trials have compared PBD and LHM.99,100 Although LHM was 
more effective for symptom relief, these were small, low-quality 
trials and one failed to meet its recruitment target. Borges et al101 
reported that LHM and PBD for achalasia were equally effective, 
even at the 2-year follow-up. In a large, high-quality, multicenter 
randomized trial involving 201 patients, there was no significant 
195
Seoul Consensus on Achalasia
Vol. 26, No. 2   April, 2020 (180-203)
difference in treatment success rate after 1, 2, and 5 years of follow-
up.25,72 Rohof et al94 reported differences in outcomes according to 
the achalasia subtype. The success rate of PBD was significantly 
higher than that of LHM for type II achalasia (100.0% vs 93.0%, 
P < 0.05).94 However, the largest difference in symptom remis-
sion rates between PBD and LHM was observed in type III 
achalasia, although the difference was not statistically significant 
due to the small number of patients in this subgroup. In addition, 
type III achalasia patients treated by PBD had significantly greater 
esophageal stasis compared to type III patients treated by LHM. 
Therefore, patients with type III seem to respond better to LHM 
than to PBD. However, RCTs comparing the outcomes of LHM 
and PBD in the various achalasia subtypes are needed to draw 
definitive conclusions. It should also be noted that PBD is a more 
cost-effective treatment option than LHM for achalasia.102,103
Statement 16: Partial fundoplication in addition to 
LHM is recommended to reduce the risk of subsequent 
GERD.
(Level of evidence, low; strength of recommendation, strong)
 Experts’ opinions: agree strongly (23.9%), agree with some 
reservations (56.5%), undecided (17.4%), disagree (2.2%), and 
disagree strongly (0.0%)
The antireflux barrier function of the LES is lost after my-
otomy, and the need to add an antireflux procedure to LHM has 
long been debated. In a meta-analysis, the rate of gastroesophageal 
reflux symptoms was reduced when fundoplication was added to 
myotomy (8.8% vs 31.5%, P = 0.001).97 However, the rate of post-
operative dysphagia was higher after LHM plus Nissen fundopli-
cation than after LHM plus Dor fundoplication (15.0% vs 2.8%, 
P = 0.001).104 In contrast, the relief of dysphagia after LHM plus 
Dor fundoplication was shown to be comparable to LHM alone.105 
In addition, 2 types of partial fundoplication (Dor and Toupet) were 
Population
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Although sufficiently long-term follow-up data are limited in comparison between POEM and LHM, both clinical efficacies of POEM and LHM
have been demonstrated in many single-arm cohort studies (moderate level of evidence for both POEM and LHM).
Patients may be recommended for POEM over LHM because POEM is a less invasive procedure than LHM (strong recommendation for POEM













This recommendation applies to almost all patients with achalasia
Patients dignosed using conventional or high resolution
manometry
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Surgically high-risk patients
Figure 7. Comparison of peroral endoscopic myotomy and laparoscopic Heller myotomy in patients with achalasia. POEM, peroral endoscopic 
myotomy; SMD, standard mean difference; LHM, laparoscopic Heller myotomy.
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comparable in terms of the degree of improvement in symptoms 
after LHM.106 Partial fundoplication reportedly decreases reflux af-
ter LHM.107 Finley et al108 reported no difference in the frequency 
or severity of reflux symptoms between patients with and without 
anterior fundoplication. However, that study was limited by the 
significant difference in preoperative upright esophageal clearance 
between the 2 groups. To draw definitive conclusions, additional 
large randomized trials are needed.
Management of Achalasia Recurrence After Initial 
Treatment
If PBD fails as a first-line treatment, additional treatment with 
PBD may be considered.67,109 PBD is also an option when symp-
toms recur after botulinum toxin injection.69 In cases showing per-
sistent or recurrent symptoms after LHM, retreatment with PBD 
may be considered.110,111 LHM is an effective treatment for the 
majority of achalasia patients. However, a small proportion of pa-
tients suffer persistent or recurrent symptoms after surgery. In such 
cases, the success rate of PBD after surgery was reported to vary 
from 50.0% to 78.0%.108-110 If the symptoms persist after POEM, 
PBD may be considered as salvage therapy depending on the clini-
cal symptoms of the patient, although there are relatively few studies 
supporting this.75,76,112
Statement 17: Peroral endoscopic myotomy is recom-
mended for achalasia patients who failed initial endo-
scopic treatment.
 (Level of evidence, moderate; strength of recommendation, 
strong)
 Experts’ opinions: agree strongly (60.9%), agree with some 
reservations (34.8%), undecided (4.3%), disagree (0.0%), and 
disagree strongly (0.0%)
The endoscopic treatment options for achalasia treatment with 
durable outcomes are PBD and POEM. Although PBD showed 
a long-term success rate of 72.0-86.0%, re-dilation was required by 
up to one-third of patients with recurrent symptoms.25,70,72,75 Young 
age, residual LES pressure > 10 mmHg, stasis on TBE, and male 
sex have been reported as predictive factors for symptom recur-
rence after PBD.113-114 POEM is a treatment option in cases for 
which PBD failed, as well as an initial treatment for achalasia (Table 
7).77,109,115-122 Large-scale observational studies including patients in 
whom PBD failed have reported that POEM is a safe and effective 
treatment option.96,117,120 Prior treatment did not increase the risk 
of POEM-related adverse events.116,119,120 However, patients with 
prior treatment showed a longer procedure time and higher rate of 
clinical failure after POEM compared to those without prior treat-
ment.120 POEM has a reported efficacy rate of > 90% based on 
short-term follow-up data. Persistence or recurrence of symptoms 
may occur after POEM. Two studies showed that redo POEM 
is feasible for patients in whom POEM failed, as a salvage option 
with a 100.0% technical success rate and an 85.0-100.0% clinical 
success rate based on short-term follow-up data.121,122 For patients 
with persistent or recurrent symptoms after POEM, redo POEM 
seems to be an efficacious and safe technique.123
In summary, POEM appears to be a safe and effective option 
for patients who failed initial endoscopic treatment. Long-term 
follow-up and randomized studies comparing other treatment op-
tions are required to define the role of POEM for cases of achalasia 
in which initial endoscopic treatment failed.
Statement 18: Peroral endoscopic myotomy can be 
considered as a rescue treatment for achalasia patients 
who were not treated successfully by Heller myotomy.
(Level of evidence, low; strength of recommendation, weak)
 Experts’ opinions: agree strongly (28.3%), agree with some 
reservations (47.8%), undecided (17.4%), disagree (6.5%), and 
disagree strongly (0.0%)
Recurrent or persistent symptoms occurred in about 10.0-
20.0% of patients who underwent LHM.25 For such patients, 
treatment options include repeat LHM, PD, or POEM. Recently, 
POEM has been used as a rescue treatment for patients who 
failed LHM. Clinical studies have reported success rates of 92.0-
98.0%.124-126 Thus, POEM could be a feasible salvage treatment 
for patients with persistent symptoms after LHM. However, ad-
ditional large studies with longer follow-up periods are necessary.
Esophagectomy
In patients with end-stage achalasia, when repeated endoscopic or 
surgical treatments are not effective, some patients may require esopha-
gectomy to relieve their symptoms. Indeed, the presence of a mega-
esophagus (maximum esophageal diameter > 6 cm), could be a pre-
dictive factor for the need of esophagectomy.127-129 In a recent systemic 
review, the postoperative morbidity ranged from 19.0% to 50.0% and 
the mortality ranged from 0.0% to 5.4%.129 Given the high morbidity 
and mortality, esophagectomy should be performed in patients with a 
megaesophagus who are fit for major surgery, complain of long-lasting 
disabling symptoms not responding to multiple endoscopic and surgi-
cal interventions, preferably in specialized centers.
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Conclusions  
The 2019 Seoul Consensus on Esophageal Achalasia Guide-
lines for esophageal achalasia introduced herein are designed to 
serve as a practical, evidence-based guide for clinicians (including 
primary physicians, gastroenterologists, upper GI tract surgeons, 
medical students, nurses, and paramedical teams) and patients. 
Esophageal manometry is the gold standard for diagnosing achala-
sia, while the Chicago classification for HRM is useful for defining 
the clinically relevant phenotypes of achalasia. Endoscopic manage-
ment (PBD or POEM) and LHM show similar efficacy with 
respect to the initial management of achalasia. POEM can serve 
as both an initial and rescue therapy for patients with achalasia, and 
may be the preferred option for patients with type III achalasia. The 
present guidelines will be updated periodically in response to new 
evidence. Prospective studies of the long-term therapeutic outcomes 
of PBD, POEM, and LHM, including their benefits and harm, 
are needed.
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